Increased speed and capacity for downstream purification? mABSOLUTELY.

INTRODUCING GORE PROTEIN CAPTURE DEVICES WITH PROTEIN A

Limitations of traditional antibody purification contribute to bottlenecks and decreased productivity in downstream processing. Understanding how this unmet need could hinder biopharmaceutical progress, Gore saw an opportunity to innovate and transform monoclonal antibody purification. Gore specialists created a family of unique protein capture devices that overcome these challenges using a novel membrane.

GORE Protein Capture Devices with Protein A are built on Gore’s in-depth knowledge of fluoropolymers and expertise when it comes to helping manufacturers maximize processing efficiency.

The growing family of Protein Capture Devices with Protein A represents Gore’s latest biopharmaceutical innovation and delivers on speed, productivity, and consistent scalability.

Increase Productivity

GORE Protein Capture Devices with Protein A utilize a unique ePTFE membrane solution that provides a binding capacity advantage at high flow rates and improves the speed of purification versus traditional technologies. Our devices are approximately 6–10x faster than traditional agarose bead-based technology.

Graph of typical dynamic binding capacity of the GORE Protein Capture Device compared with a standard agarose bead-based technology, using a purified monoclonal antibody.

Typical dynamic binding capacity of the GORE Protein Capture Device compared with a standard agarose bead-based technology, using a purified monoclonal antibody. GORE Protein Capture Devices are approximately 6–10x faster.

Applications

Designed for affinity purification in early drug discovery screening, late-stage optimization, process development, and clinical applications for monoclonal antibodies (mAbs) and next-generation molecules that utilize the FC region for Protein A binding.

Protein capture graphic

Consistent Scalability

The GORE Protein Capture Device with Protein A currently features six sizes to support process development to preclinical and early commercial manufacturing with consistent scalability. When Gore introduces its next two larger sizes, coming in 2023, bioprocessors will have a completely scalable chromatography platform that enables intensified downstream processing for clinical and targeted batch production.

Larger sizes coming soon!

Compliance and Quality

GORE Protein Capture Devices with Protein A are manufactured following the applicable material quality and regulatory requirements, including relevant Good Manufacturing Processes as defined in the Gore PharmBIO quality system, which is certified to ISO 13485 and ISO 15378.

Two men looking at a computer screen

Ready to transform your purification processes? mABSOLUTELY.

Request a sample of the GORE Protein Capture Device with Protein A for your internal testing by completing the form on the right.

Upcoming Events